Chen RW - Search Results

1

RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.

Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. Chen RW, et al. Br J Haematol. 2017 Mar;176(5):759-769. doi: 10.1111/bjh.14480. Epub 2016 Dec 19. Br J Haematol. 2017. PMID: 27992063 Free PMC article. Clinical Trial.

2

Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma.

Chen R, Palmer JM, Popplewell L, Shen J, Smith E, Delioukina M, Kogut N, Rosenthal J, Forman S, Nademanee A. Chen R, et al. Ann Hematol. 2011 Jul;90(7):803-8. doi: 10.1007/s00277-010-1146-3. Epub 2011 Jan 6. Ann Hematol. 2011. PMID: 21210120

3

Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines.

Tiemann K, Alluin JV, Honegger A, Chomchan P, Gaur S, Yun Y, Forman SJ, Rossi JJ, Chen RW. Tiemann K, et al. Among authors: chen rw. Leuk Lymphoma. 2011 Nov;52(11):2148-54. doi: 10.3109/10428194.2011.593272. Epub 2011 Jul 12. Leuk Lymphoma. 2011. PMID: 21745168 Free PMC article.

4

A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.

Kirschbaum MH, Stein AS, Popplewell L, Delioukina M, Chen R, Nakamura R, Snyder D, Conrad J, Lacey SF, Frankel P, Dagis A, Nademanee A, Forman SJ. Kirschbaum MH, et al. Biol Blood Marrow Transplant. 2012 Mar;18(3):432-40. doi: 10.1016/j.bbmt.2011.07.017. Epub 2011 Jul 27. Biol Blood Marrow Transplant. 2012. PMID: 21801703 Free article. Clinical Trial.

5

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R. Younes A, et al. J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454421 Free PMC article. Clinical Trial.

6

Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.

Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Winter JN, Yahalom J, Sundar H; National Comprehensive Cancer Network. Hoppe RT, et al. J Natl Compr Canc Netw. 2012 May;10(5):589-97. doi: 10.6004/jnccn.2012.0061. J Natl Compr Canc Netw. 2012. PMID: 22570290

7

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.

Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A, Forman SJ, Gopal AK. Chen R, et al. Blood. 2012 Jun 28;119(26):6379-81. doi: 10.1182/blood-2012-03-418673. Epub 2012 May 18. Blood. 2012. PMID: 22611160 Free PMC article.

8

Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells.

Zhou J, Tiemann K, Chomchan P, Alluin J, Swiderski P, Burnett J, Zhang X, Forman S, Chen R, Rossi J. Zhou J, et al. Nucleic Acids Res. 2013 Apr;41(7):4266-83. doi: 10.1093/nar/gkt125. Epub 2013 Mar 6. Nucleic Acids Res. 2013. PMID: 23470998 Free PMC article.

9

Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy.

Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, Matous JV, Shustov AR, Smith SE, Zain J, O'Meara MM, Fanale MA. Gopal AK, et al. Leuk Lymphoma. 2014 Oct;55(10):2328-34. doi: 10.3109/10428194.2013.876496. Epub 2014 Feb 24. Leuk Lymphoma. 2014. PMID: 24359243

10

Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma.

Chen R, Palmer JM, Tsai NC, Thomas SH, Siddiqi T, Popplewell L, Farol L, Nademanee A, Forman SJ. Chen R, et al. Biol Blood Marrow Transplant. 2014 Nov;20(11):1864-8. doi: 10.1016/j.bbmt.2014.06.037. Epub 2014 Jul 5. Biol Blood Marrow Transplant. 2014. PMID: 25008328 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

242 results

Search Page

Filters